MBX

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 64.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MBX Biosciences Inc revenue for the last quarter amounts to -23.93M USD, increased 22.00 % YoY.

MBX Biosciences Inc. EPS for the last quarter amounts to -21935000.00 USD, increased 49.00 % YoY.

MBX Biosciences Inc (MBX) has 43 emplpoyees as of December 16 2025.

Today MBX has the market capitalization of 1.27B USD.